Unresponsiveness to PD-1/PD-L1 blockade therapies has been reported previously in advanced stages of lymphoma, a process that was overcome by local delivery of an armed anti-PD-L1 antibody with type I interferon-α to create feedforward responses.41 This evidence concerns the gene PDCD1 and lymphoma.